Vojdani, A, Ghoneum, M, Choppa, P C et al. · Journal of internal medicine · 1997 · DOI
This study found that immune cells in ME/CFS patients are dying at higher rates than in healthy people. The researchers discovered that a molecule called PKR, which is produced in response to infections, is abnormally elevated in ME/CFS patients and may be triggering this excess cell death. When they blocked PKR in the lab, they were able to reduce cell death in about half of the ME/CFS samples, suggesting PKR might be a key player in ME/CFS disease.
This study identifies a potential molecular mechanism underlying ME/CFS—excessive immune cell death mediated by PKR—which could explain the persistent immune dysfunction and fatigue symptoms. If validated in larger studies, PKR inhibition could represent a novel therapeutic target for treating ME/CFS.
This study does not prove that PKR elevation causes ME/CFS, only that it is associated with the disease and may contribute to cell death. The cross-sectional design cannot establish temporal relationships or causality. Additionally, the in vitro PKR inhibition does not demonstrate that blocking PKR would improve clinical symptoms in ME/CFS patients, and the 50% response rate suggests PKR is not the sole mechanism of apoptosis in all patients.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →